Misconceptions and misinformation mean India's child immunization program has failed

11 September 2017
india_big_li

Mandatory immunization for children in India between nine months and 15 years of age against measles and rubella has not worked its charm, with India and Indonesia accounting for over 90% of unvaccinated children in Southeast Asia, according to the World Health Organization. Misconceptions and misinformation have turned out to be the main culprit, reports The Pharma Letter’s India correspondent.

According to the Southeast Asia Regional Office of the World Health Organization (WHO), 3.1 million children in India and 1.1 million in Indonesia did not get the measles vaccination in 2016. Together, they account for 91% of unvaccinated children in the region, with India alone accounting for 67% of the children missing immunisation. Measles still kills an estimated 134,200 children worldwide every year, which includes more than 54,500 in Southeast Asia alone.

India's measles elimination campaign was rocked by rumors and fake alerts claiming the vaccine is banned in the USA for causing serious side effects, including damaging a child’s immunity and memory and is allegedly being pushed in India by Big Pharma looking for an easy market to dump their products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical